SEARCH

SEARCH BY CITATION

References

  • Aguado T, Carracedo A, Julien B, Velasco G, Milman G, Mechoulam R et al. (2007). Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem 282: 68546862.
  • Amaya F, Shimosato G, Kawasaki Y, Hashimoto S, Tanaka Y, Ji R-R et al. (2006). Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 124: 175183.
  • Barann M, Molderings G, Brüss M, Bönisch H, Urban BW, Göthert M (2002). Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137: 589596.
  • Bayewitch M, Rhee M-H, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z (1996). Δ9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271: 99029905.
  • Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S et al. (2006). CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23: 15301538.
  • Berrendero F, Maldonado R (2002). Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol. Psychopharmacology 163: 111117.
  • Berrendero F, Sánchez A, Cabranes A, Puerta C, Ramos JA, García-Merino A et al. (2001). Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41: 195202.
  • Bifulco M, Laezza C, Gazzerro P, Pentimalli F (2007). Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review). Oncol Rep 17: 813816.
  • Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845852.
  • Blázquez C, Carracedo A, Barrado L, Real PJ, Fernández-Luna JL, Velasco G et al. (2006). Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 20: 26332635.
  • Braida D, Iosuè S, Pegorini S, Sala M (2004). Δ9-Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol 506: 6369.
  • Braida D, Limonta V, Malabarba L, Zani A, Sala M (2007). 5-HT1A receptors are involved in the anxiolytic effect of Δ9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague–Dawley rats. Eur J Pharmacol 555: 156163.
  • Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim Selley LJ (1999). Chronic Δ9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73: 24472459.
  • Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155163.
  • Brown N, Harvey D (1988). In vivo metabolism of the n-propyl homologues of delta-8- and delta-9-tetrahydrocannabinol in the mouse. Biomed Environ Mass Spectrom 15: 403410.
  • Busch-Petersen J, Hill WA, Fan P, Khanolkar A, Xie X-Q, Tius MA et al. (1996). Unsaturated side chain β-11-hydroxyhexahydrocannabinol analogs. J Med Chem 39: 37903796.
  • Cabral GA, Staab A (2005). Effects on the immune system. In: Pertwee RG (ed). Cannabinoids. Handbook of Experimental Pharmacology, vol. 168. Springer-Verlag: Heidelberg. pp 385423.
  • Cabranes A, Pryce G, Baker D, Fernández-Ruiz J (2006). Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res 1107: 199205.
  • Carracedo A, Gironella M, Lorente M, Garcia S, Guzmán M, Velasco G et al. (2006). Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 66: 67486755.
  • Carrier EJ, Auchampach JA, Hillard CJ (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103: 78957900.
  • Cawthorne MA, Wargent E, Zaibi M, Stott C, Wright S (2007). The CB-1 antagonist, delta-9-tetrahydrocannabivarin (THCV) has anti-obesity activity in dietary-induced obese (DIO) mice. Symposium on the Cannabinoids. Burlington, Vermont, USA. International Cannabinoid Research Society, p 141.
  • Cheer JF, Cadogan A-K, Marsden CA, Fone KCF, Kendall DA (1999). Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38: 533541.
  • Childers SR (2006). Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS J 8: E112E117.
  • Chiu P, Olsen DM, Borys HK, Karler R, Turkanis SA (1979). The influence of cannabidiol and Δ9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia 20: 365375.
  • Christopoulos A, Wilson K (2001). Interaction of anandamide with the M1 and M4 muscarinic acetylcholine receptors. Brain Res 915: 7078.
  • Colasanti BK, Lindamood C, Craig CR (1982). Effects of marihuana cannabinoids on seizure in cobalt-epileptic rats. Pharmacol Biochem Behav 16: 573578.
  • Darmani NA, Crim JL (2005). Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav 80: 3544.
  • Darmani NA, Johnson JC (2004). Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488: 201212.
  • De Vry J, Jentzsch KR, Kuhl E, Eckel G (2004). Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15: 112.
  • Dennis I, Whalley B, Stephens G (2007). Effects of cannabinoids on [35S]GTPγS binding in specific regions of the mouse brain. Poster P041 at the Joint Focused Meeting/3rd European Workshop on Cannabinoid Research, University of Nottingham, UK, 20 and 21 April 2007. Focused Meeting of the British Pharmacological Society.
  • Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 19461949.
  • Dewey WL (1986). Cannabinoid pharmacology. Pharmacol Rev 38: 151178.
  • Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM et al. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain. J Neurochem 75: 24342444.
  • Di Marzo V, De Petrocellis L, Bisogno T (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. In: Pertwee RG (ed). Cannabinoids. Handbook of Experimental Pharmacology, Vol 168. Springer-Verlag: Heidelberg. pp 147185.
  • Drysdale AJ, Ryan D, Pertwee RG, Platt B (2006). Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. Neuropharmacology 50: 621631.
  • Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48: 443450.
  • Fish BS, Consroe P, Fox RR (1983). Convulsant–anticonvulsant properties of delta-9-tetrahydrocannabinol in rabbits. Behav Genet 13: 205211.
  • Fox A, Bevan S (2005). Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs 14: 695703.
  • Gardner EL (2005). Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81: 263284.
  • Gauson LA, Stevenson LA, Thomas A, Baillie GL, Ross RA, Pertwee RG (2007). Cannabigerol behaves as a partial agonist at both CB1 and CB2 receptors. Symposium on the Cannabinoids. Burlington, Vermont, USA. International Cannabinoid Research Society, p 206.
  • Gill EW, Paton WDM, Pertwee RG (1970). Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 228: 134136.
  • Gong J-P, Onaivi ES, Ishiguro H, Liu Q-R, Tagliaferro PA, Brusco A et al. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071: 1023.
  • Göthert M, Brüss M, Bönisch H, Molderings GJ (1999). Presynaptic imidazoline receptors: new developments in characterization and classification. Ann NY Acad Sci 881: 171184.
  • Guzmán M (2003). Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745755.
  • Guzmán M (2005). Effects on cell viability. In: Pertwee RG (ed). Cannabinoids. Handbook of Experimental Pharmacology, vol. 168. Springer-Verlag: Heidelberg. pp 627642.
  • Guzmán M, Duarte MJ, Blazquez C, Ravina J, Rosa MC, Galve-Roperh I et al. (2006). A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 95: 197203.
  • Hájos N, Freund TF (2002). Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43: 503510.
  • Haller J, Mátyas F, Soproni K, Varga B, Barsy B, Németh B et al. (2007). Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 25: 24452456.
  • Haller VL, Cichewicz DL, Welch SP (2006). Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur J Pharmacol 546: 6068.
  • Hejazi N, Zhou C, Oz M, Sun H, Ye JH, Zhang L (2006). Δ9-Tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol 69: 991997.
  • Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al. (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87: 19321936.
  • Herrera B, Carracedo A, Diez-Zaera M, del Pulgar TG, Guzmán M, Velasco G (2006). The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res 312: 21212131.
  • Hollister LE (1974). Structure–activity relationships in man of cannabis constituents and homologs and metabolites of Δ9-tetrahydrocannabinol. Pharmacology 11: 311.
  • Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161202.
  • Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL et al. (1999). 3-(1′,1′-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7: 29052914.
  • Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (2001). In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 296: 420425.
  • Izzo AA, Capasso F, Costagliola A, Bisogno T, Marsicano G, Ligresti A et al. (2003). An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125: 765774.
  • Izzo AA, Coutts AA (2005). Cannabinoids and the digestive tract. In: Pertwee RG (ed). Cannabinoids. Handbook of Experimental Pharmacology, Vol 168. Springer-Verlag: Heidelberg. pp 573598.
  • Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T et al. (2001). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134: 563570.
  • Järbe TUC, DiPatrizio NV (2005). Δ9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist Δ9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. Behav Pharmacol 16: 373380.
  • Jin KL, Mao XO, Goldsmith PC, Greenberg DA (2000). CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 48: 257261.
  • Justinova Z, Goldberga SR, Heishman SJ, Tanda G (2005). Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 81: 285299.
  • Kathmann M, Flau K, Redmer A, Trankle C, Schlicker E (2006). Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedebergs Arch Pharmacol 372: 354361.
  • Kelley BG, Thayer SA (2004). Δ9-Tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 46: 709715.
  • Kim K, Moore DH, Makriyannis A, Abood ME (2006). AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 542: 100105.
  • Kimball ES, Schneider CR, Wallace NH, Hornby PJ (2006). Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 291: G364G371.
  • Kishimoto S, Muramatsu M, Gokoh M, Oka S, Waku K, Sugiura T (2005). Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem 137: 217223.
  • Koch M, Dehghani F, Habazettl I, Schomerus C, Korf H-W (2006). Cannabinoids attenuate norepinephrine-induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N-acetyltransferase activity without involvement of cannabinoid receptors. J Neurochem 98: 267278.
  • Kreitzer AC (2005). Neurotransmission: emerging roles of endocannabinoids. Curr Biol 15: R549R551.
  • Lam PMW, McDonald J, Lambert DG (2005). Characterization and comparison of recombinant human and rat TRPV1 receptors: effects of exo- and endocannabinoids. Br J Anaesth 94: 649656.
  • Le Foll B, Goldberg SR (2005). Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312: 875883.
  • Lemberger L, Martz R, Rodda B, Forney R, Rowe H (1973). Comparative pharmacology of Δ9-tetrahydrocannabinol and its metabolite, 11-hydroxy-Δ9-tetrahydrocannabinol. J Clin Invest 52: 24112417.
  • Lichtman AH, Martin BR (2005). Cannabinoid tolerance and dependence. In: Pertwee RG (ed). Cannabinoids. Handbook of Experimental Pharmacology, Vol 168. Springer-Verlag: Heidelberg. pp 691717.
  • Lim G, Sung B, Ji R-R, Mao J (2003). Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105: 275283.
  • Limebeer CL, Hall G, Parker LA (2006). Exposure to a lithium-paired context elicits gaping in rats: a model of anticipatory nausea. Physiol Behav 88: 398403.
  • Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT et al. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316: 780788.
  • Ma Y-L, Whalley BJ, Stephens GJ (2006). The phytocannabinoid Δ9-tetrahydrocannabivarin modulates synaptic transmission at central inhibitory synapses. Proc Br Pharmacol Soc at http://www.pa2online.org/abstract/abstract.jspabid=28558&author=Whalley&cat=7&period=29.
  • MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW (1998a). Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 124: 619622.
  • MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW, Martin GR (1998b). [35S]GTPγS binding to assess inverse agonist actions of ligands at human recombinant CB1 and CB2 receptors. Symposium on the Cannabinoids. Burlington, Vermont, USA. International Cannabinoid Research Society. p 7.
  • Maldonado R, Valverde O, Berrendero F (2006). Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29: 225232.
  • Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S (2007). Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets 11: 403409.
  • Mang CF, Erbelding D, Kilbinger H (2001). Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br J Pharmacol 134: 161167.
  • Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN (2005). Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95: 437445.
  • Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP et al. (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13: 492497.
  • Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK et al. (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40: 471478.
  • Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF et al. (2004). The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 12021209.
  • Matias I, Di Marzo V (2007). Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18: 2737.
  • Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561564.
  • McAllister SD, Chan C, Taft RJ, Luu T, Abood ME, Moore DH et al. (2005). Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol 74: 3140.
  • McHugh D, Ross RA (2005). Endocannabinoids and phytocannabinoids inhibit human neutrophil migration. Symposium on the Cannabinoids. Burlington, Vermont, USA. International Cannabinoid Research Society. p 38.
  • McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu SH, Grant S et al. (2002). Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100: 627634.
  • Mechoulam R (2005). Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol 146: 913915.
  • Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 8390.
  • Mendizábal VE, Adler-Graschinsky E (2007). Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol 151: 427440.
  • Merkus FWHM (1971). Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish. Nature 232: 579580.
  • Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H et al. (2006). Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126: 102114.
  • Molderings GJ, Bönisch H, Hammermann R, Göthert M, Brüss M (2002). Noradrenaline release-inhibiting receptors on PC12 cells devoid of α2- and CB1 receptors: similarities to presynaptic imidazoline and edg receptors. Neurochem Int 40: 157167.
  • Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R et al. (2006). The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51: 455466.
  • Monory K, Tzavara ET, Lexime J, Ledent C, Parmentier M, Borsodi A et al. (2002). Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun 292: 231235.
  • Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 6165.
  • Nagai H, Egashira N, Sano K, Ogata A, Mizuki A, Mishima K et al. (2006). Antipsychotics improve Δ9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacol Biochem Behav 84: 330336.
  • O'Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD (2005). Novel time-dependent vascular actions of Δ9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337: 824831.
  • Oz M (2006). Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol Ther 111: 114144.
  • Parker LA, Limebeer CL, Kwiatkowska M (2005). Cannabinoids: effects on vomiting and nausea in animal models. In: Mechoulam R (ed). Cannabinoids as Therapeutics. Birkhaüser Verlag: Basel. pp 183200.
  • Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P (2003). Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 166: 156162.
  • Patel S, Hillard CJ (2006). Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318: 304311.
  • Pertwee RG (1988). The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 36: 189261.
  • Pertwee RG (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129180.
  • Pertwee RG (1999). Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6: 635664.
  • Pertwee RG (2004a). Pharmacological and therapeutic targets for Δ9-tetrahydrocannabinol and cannabidiol. Euphytica 140: 7382.
  • Pertwee RG (2004b). The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V (ed). Cannabinoids. Kluwer Academic/Plenum Publishers: New York. pp 3283.
  • Pertwee RG (2004c). Novel pharmacological targets for cannabinoids. Curr Neuropharmacol 2: 929.
  • Pertwee RG (2005a). Pharmacological actions of cannabinoids. In: Pertwee RG (ed). Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168. Springer-Verlag: Heidelberg. pp 151.
  • Pertwee RG (2005b). The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 7: E625E654.
  • Pertwee RG (2005c). Cannabidiol as a potential medicine. In: Mechoulam R (ed). Cannabinoids as Therapeutics. Birkhaüser Verlag: Basel. pp 4765.
  • Pertwee RG (2006). Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147: S163S171.
  • Pertwee RG (2007a). Cannabinoids and multiple sclerosis. Mol Neurobiol (in press).
  • Pertwee RG (2007b). GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol (in press).
  • Pertwee RG, Ross RA (2002). Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66: 101121.
  • Pertwee RG, Ross RA, Craib SJ, Thomas A (2002). Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456: 99106.
  • Pertwee RG, Stevenson LA, Ross RA, Gauson LA, Thomas A (2007a). Signs of cannabinoid CB2 receptor activation by tetrahydrocannabivarin, cannabigerol and cannabidiol. IACM Fourth Conference on Cannabinoids in Medicine (in press).
  • Pertwee RG, Thomas A (2007). Therapeutic applications for agents that act at CB1 and CB2 receptors. In: Reggio PH (ed). The Cannabinoid Receptors. The Humana Press: Totowa, NJ, (in press).
  • Pertwee RG, Thomas A, Stevenson LA, Ross RA, Varvel SA, Lichtman AH et al. (2007b). The psychoactive plant cannabinoid, Δ9-tetrahydrocannabinol, is antagonized by Δ8- and Δ9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150: 586594.
  • Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq M-C (1998). Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: PL1PL6.
  • Pisanu A, Acquas E, Fenu S, Di Chiara G (2006). Modulation of Δ9THC-induced increase of cortical and hippocampal acetylcholine release by mu opioid and D-1 dopamine receptors. Neuropharmacology 50: 661670.
  • Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL et al. (2002). Δ9-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948: 155158.
  • Pryce G, Baker D (2007). Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 150: 519525.
  • Rakhshan F, Day TA, Blakely RD, Barker EL (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292: 960967.
  • Rhee M-H, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L et al. (1997). Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 40: 32283233.
  • Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240244.
  • Robinson L, Fadda P, McKillop-Smith S, Fratta W, Pertwee RG, Riedel G (2007). Phytocannabinoid induced anorexic behaviour in fasted and non-fasted mice. IACM Fourth Conference on Cannabinoids in Medicine (in press).
  • Robson P (2005). Human studies of cannabinoids and medicinal cannabis. In: Pertwee RG (ed). Cannabinoids. Handbook of Experimental Pharmacology, vol. 168. Springer-Verlag: Heidelberg. pp 719756.
  • Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG et al. (2001). Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40: 221232.
  • Russo EB, Burnett A, Hall B, Parker KK (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 10371043.
  • Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N-O, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol (in press).
  • Sacerdote P, Martucci C, Vaccani A, Bariselli F, Panerai AE, Colombo A et al. (2005). The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 159: 97105.
  • Sanson M, Bueno L, Fioramonti J (2006). Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 18: 949956.
  • Sarfaraz S, Afaq F, Adhami VM, Mukhtar H (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65: 16351641.
  • Schramm-Sapyta NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM (2007). Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology 191: 867877.
  • Shen M, Thayer SA (1999). Δ9-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55: 813.
  • Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL (2007). The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101: 8798.
  • Showalter VM, Compton DR, Martin BR, Abood ME (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989999.
  • Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J (2001). Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415: R5R7.
  • Sim LJ, Hampson RE, Deadwyler SA, Childers SR (1996). Effects of chronic treatment with Δ9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPγS autoradiography in rat brain. J Neurosci 16: 80578066.
  • Sim-Selley LJ (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15: 91119.
  • Sim-Selley LJ, Martin BR (2002). Effect of chronic administration of R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or Δ9-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 303: 3644.
  • Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L et al. (1996). The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 93: 39843989.
  • Steffens S, Mach F (2006). Cannabinoid receptors in atherosclerosis. Curr Opin Lipidol 17: 519526.
  • Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C et al. (2005). Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782786.
  • Straiker A, Mackie K (2005). Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569: 501517.
  • Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Comm 215: 8997.
  • Szabo B, Schlicker E (2005). Effects of cannabinoids on neurotransmission. In: Pertwee RG (ed). Cannabinoids. Handbook of Experimental Pharmacology, Vol 168. Springer-Verlag: Heidelberg. pp 327365.
  • Szczesniak AM, Kelly MEM, Whynot S, Shek PN, Hung O (2006). Ocular hypotensive effects of an intratracheally delivered liposomal delta-9-tetrahydrocannabinol preparation in rats. J Ocul Pharmacol Ther 22: 160167.
  • Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613623.
  • Thomas A, Ross RA, Saha B, Mahadevan A, Razdan RK, Pertwee RG (2004). 6″-Azidohex-2″-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur J Pharmacol 487: 213221.
  • Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA et al. (2005). Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146: 917926.
  • Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ (2006). Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 15: 349353.
  • Tomida I, Pertwee RG, Azuara-Blanco A (2004). Cannabinoids and glaucoma. Br J Ophthalmol 88: 708713.
  • Turkanis SA, Karler R (1981). Electrophysiologic properties of the cannabinoids. J Clin Pharmacol 21: 449S463S.
  • Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329332.
  • Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003). Δ9-Tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285: G566G576.
  • Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, Lichtman AH (2005). Δ9-Tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther 314: 329337.
  • Vaughan CW, Christie MJ (2005). Retrograde signalling by endocannabinoids. In: Pertwee RG (ed). Cannabinoids. Handbook of Experimental Pharmacology, Vol 168. Springer-Verlag: Heidelberg. pp 367383.
  • Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390: 518521.
  • Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2006). Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res 83: 13101322.
  • Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ (2003). The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307: 129137.
  • Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ (2001). Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 428: 5157.
  • Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G et al. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 13981405.
  • Walter L, Stella N (2004). Cannabinoids and neuroinflammation. Br J Pharmacol 141: 775785.
  • Watanabe K, Kijima T, Narimatsu S, Nishikami J, Yamamoto I, Yoshimura H (1990). Comparison of pharmacological effects of tetrahydrocannabinols and their 11-hydroxy-metabolites in mice. Chem Pharm Bull 38: 23172319.
  • Weston S, Williamson EM, Constanti A, Stephens G, Whalley B (2006). Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity. Proc Br Pharmacol Soc at http://www.pa2online.org/abstract/abstract.jspabid=28533&author=Whalley&cat=7&period=29.
  • Whiteside GT, Lee GP, Valenzano KJ (2007). The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14: 917936.
  • Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A et al. (2005a). CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145: 293300.
  • Wiley JL, Jefferson RG, Grier MC, Mahadevan A, Razdan RK, Martin BR (2001). Novel pyrazole cannabinoids: insights into CB1 receptor recognition and activation. J Pharmacol Exp Ther 296: 10131022.
  • Wiley JL, Smith FL, Razdan RK, Dewey WL (2005b). Task specificity of cross-tolerance between Δ9-tetrahydrocannabinol and anandamide analogs in mice. Eur J Pharmacol 510: 5968.
  • Wilkinson JD, Williamson EM (2007). Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci 45: 8792.
  • Wilson RS, May EL (1975). Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs. J Med Chem 18: 700703.
  • Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135: 235245.
  • Xu H, Cheng B, Manivannan A, Cabay L, Pertwee RG, Coutts A et al. (2007). Anti-inflammatory property of the cannabinoid receptor-2 selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol 82 [e-pub ahead of print].
  • Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J et al. (2006). Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171: 3138.
  • Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C et al. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6 at http://www.biomedcentral.com/1471-2377/6/12.
  • Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D (2003). Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17: 27502754.
  • Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96: 57805785.
  • Zygmunt PM, Andersson DA, Högestätt ED (2002). Δ9-Tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 22: 47204727.